Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | +1.85% | +16.40% | -81.17% |
Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
Apr. 04 | Top Midday Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.35M |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
Net cash position 2024 * | 22M | Net cash position 2025 * | 58M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-1.08
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.91% |
Latest transcript on eFFECTOR Therapeutics, Inc.
1 day | +1.85% | ||
1 week | +16.40% | ||
Current month | -2.22% | ||
1 month | -25.68% | ||
3 months | -79.17% | ||
6 months | -83.43% | ||
Current year | -81.17% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Michael Byrnes
DFI | Director of Finance/CFO | 47 | 20-11-30 |
Douglas Warner
CTO | Chief Tech/Sci/R&D Officer | 52 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Director/Board Member | 54 | 21-08-24 | |
Caroline Loewy
BRD | Director/Board Member | 58 | 23-09-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 2.2 | +1.85% | 144,765 |
24-05-02 | 2.16 | -1.82% | 108,688 |
24-05-01 | 2.2 | -2.22% | 63,095 |
24-04-30 | 2.25 | +8.70% | 188,873 |
24-04-29 | 2.07 | +9.52% | 227,837 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-81.17% | 10.35M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- EFTR Stock